Natixis Advisors LLC Acquires 98,554 Shares of Edwards Lifesciences Co. (NYSE:EW)

Natixis Advisors LLC grew its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 51.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 288,443 shares of the medical research company's stock after buying an additional 98,554 shares during the quarter. Natixis Advisors LLC's holdings in Edwards Lifesciences were worth $21,353,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter worth approximately $30,000. FSA Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the third quarter worth $32,000. Avior Wealth Management LLC increased its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after buying an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $46,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

Shares of EW traded down $0.50 during trading hours on Friday, hitting $70.46. The stock had a trading volume of 7,144,270 shares, compared to its average volume of 4,605,776. The stock has a market capitalization of $41.42 billion, a price-to-earnings ratio of 10.11, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company's fifty day moving average is $71.48 and its two-hundred day moving average is $70.35. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CEO Bernard J. Zovighian sold 6,164 shares of the company's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now directly owns 59,083 shares in the company, valued at approximately $4,106,859.33. This represents a 9.45 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 500 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. This trade represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 51,303 shares of company stock worth $3,715,776. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on EW. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Piper Sandler increased their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Truist Financial reiterated a "hold" rating and issued a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Canaccord Genuity Group raised their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.